Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for FibroBiologics Inc. (FBLG : NSDQ)

• Company Description    FibroBiologics Inc. is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics Inc. is based in HOUSTON. Number of Employees: 15

• Price / Volume Information    Yesterday's Closing Price: $0.71 Daily Weekly Monthly 20 Day Moving Average: 134,978 shares Shares Outstanding: 6.08 (millions) Market Capitalization: $4.33 (millions) Beta: 1.14 52 Week High: $14.40 52 Week Low: $0.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.89% -3.61% 12 Week -46.06% -47.54% Year To Date -84.17% -84.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9350 Kirby Drive Suite 300 - HOUSTON,TX 77054 USA ph: 281-671-5150 fax: - fibrobiologicsir@russopr.com http://www.fibrobiologics.com

• General Corporate Information    Officers Pete O'Heeron - Chief Executive Officer and Chairperson Jason D. Davis - Chief Financial Officer Richard Cilento - Director Stacy Coen - Director Robert E. Hoffman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 31573L204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/30/26 Share - Related Items Shares Outstanding: 6.08 Most Recent Split Date: 3.00 (0.05:1) Beta: 1.14 Market Capitalization: $4.33 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.94 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 52.50% vs. Previous Quarter: -121.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -767.07 12/31/25 - -785.84 ROA 06/30/26 - - 03/31/26 - -195.56 12/31/25 - -170.69 Current Ratio 06/30/26 - - 03/31/26 - 1.59 12/31/25 - 3.61 Quick Ratio 06/30/26 - - 03/31/26 - 1.59 12/31/25 - 3.61 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 0.74 12/31/25 - 1.85 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©